VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
ATG-Sirolimus-Tacrolimus
Preclinical
Small molecule
U
Universitair Ziekenhuis Brussel
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Type 1 Diabetic
Terminated
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Type 1 Diabetic
Preclinical
Terminated
Clinical
Trials by Indication
[1]
Type 1 Diabetic
1 trial
Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts
Terminated
·
U
Universitair Ziekenhuis Brussel
·
N/A
·
NCT00409461
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for ATG-Sirolimus-Tacrolimus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
ATG-Sirolimus-Tacrolimus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for ATG-Sirolimus-Tacrolimus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Universitair Ziekenhuis Brussel company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
U
Universitair Ziekenhuis Brussel
Related News